Zydus Lifesciences, formerly known as Zydus Cadila, is a prominent player in the global pharmaceutical industry, headquartered in India. Founded in 1995, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Zydus Lifesciences focuses on research and development, manufacturing, and marketing of a diverse range of healthcare products, including generic medicines, biosimilars, and vaccines. With a commitment to innovation, Zydus Lifesciences has achieved significant milestones, such as the development of India's first indigenously produced DNA vaccine. The company is recognised for its robust portfolio of over 1,000 products, which cater to various therapeutic areas, making it a key player in the pharmaceutical market. Zydus Lifesciences continues to enhance its market position through strategic partnerships and a dedication to improving global health outcomes.
How does Zydus Lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Zydus Lifesciences's score of 46 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Zydus Lifesciences reported total carbon emissions of approximately 307,413,650 kg CO2e, comprising 44,972,560 kg CO2e from Scope 1, 192,676,190 kg CO2e from Scope 2, and 24,393,000 kg CO2e from Scope 3 emissions. The company has set a significant climate commitment to achieve carbon neutrality in its operations for Scope 1 and Scope 2 emissions by FY2035. This long-term target reflects Zydus Lifesciences's dedication to reducing its carbon footprint and addressing climate change. In 2023, the total emissions were about 279,068,020 kg CO2e, with Scope 1 emissions at 44,792,270 kg CO2e and Scope 2 emissions at 175,980,980 kg CO2e. The previous year, 2022, saw total emissions of approximately 255,889,000 kg CO2e, indicating a trend in emissions management. Zydus Lifesciences is actively working towards its climate goals, focusing on reducing emissions across all scopes, particularly in its operational activities. The company's commitment to sustainability is evident in its structured approach to achieving net-zero emissions in the coming years.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Scope 1 | 2,409,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 10,039,000 | 0,000,000 | 00,000,000 | 0,000,000 | 000,000,000 |
Scope 3 | - | - | 0,000,000 | 00,000,000 | 00,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zydus Lifesciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.